IL2 and autoimmune disease: Our reports confirms that the Treg population rather than effector T cell subset is dependent on IL-2 availability and points to the possibility that low-dose IL-2 immunotherapy may provide a mechanism for recovering the selective expansion of Tregs for the suppression of autoimmune disorders, especially those ongoing with IL-2 systemic deficit.